Endurant Capital Management LP Ascendis Pharma A/S Transaction History

Endurant Capital Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 15, 2018	SELL	$38.98 - $68.04 $1.47 Million - $2.57 Million	-37,828 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$31.98 - $40.38 $655,526 - $827,709	20,498 Added 118.28%	37,828 $1.52 Million
Q3 2017 Nov 14, 2017	BUY	$26.89 - $37.1 $466,003 - $642,943	17,330	17,330 $628,000

210

46.5M

310K

306K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.58B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.